Background/Objectives: There is an increasing incidence of fungal infections in conjunction with the rise in resistance to medical treatment. Antimicrobial resistance is frequently associated with virulence factors such as adherence and the capacity of biofilm formation, which facilitates the evasion of the host immune response and resistance to drug action. Novel therapeutic strategies have been developed to overcome antimicrobial resistance, including the use of different type of nanomaterials: metallic (Au, Ag, Fe3O4 and ZnO), organic (e.g., chitosan, liposomes and lactic acid) or carbon-based (e.g., quantum dots, nanotubes and graphene) materials. The objective of this study was to evaluate the action of nanoparticles of different synthesis and with different coatings on fungi of medical interest. Methods: Literature research was conducted using PubMed and Google Scholar databases, and the following terms were employed in articles published up to June 2025: ‘nanoparticles’ in combination with ‘fungal biofilm’, ‘Candida biofilm’, ‘Aspergillus biofilm’, ‘Cryptococcus biofilm’, ‘Fusarium biofilm’ and ‘dermatophytes biofilm’. Results: The utilization of nanoparticles was found to exert a substantial impact on the reduction in fungal biofilm, despite the presence of substantial variability in minimum inhibitory concentration (MIC) values attributable to variations in nanoparticle type and the presence of capping agents. It was observed that the MIC values were lower for metallic nanoparticles, particularly silver, and for those synthesized with polylactic acid compared to the others. Conclusions: Despite the limited availability of data concerning the stability and biocompatibility of nanoparticles employed in the treatment of fungal biofilms, it can be posited that these results constitute a significant initial step.
Background: Antifungal resistance among Candida species and related genera, coupled with the lack of new drugs, poses a significant threat to public health. Several studies have demonstrated a relationship between virulence factors and resistance. Current objectives include identifying new targets and searching for new natural molecules. Carvacrol, a natural phenolic compound, has been shown to have antimicrobial properties; however, its impact on the virulence of species other than Candida albicans and related yeast genera remains underexplored. Methods: The antifungal activity of carvacrol was evaluated against clinical isolates of Candidozyma auris, Meyerozyma guilliermondii, and Candida dubliniensis, as well as its effect on adhesion, hydrophobicity, biofilm formation and osmotic stress tolerance. In vivo activity was assessed using the Galleria mellonella infection model at MIC concentrations. Results: Carvacrol inhibited adherence and significantly reduced both early and preformed biofilms in M. guilliermondii and C. dubliniensis. In C. auris, the compound produced a modest reduction in biofilm activity but significantly enhanced larval survival in the in vivo model (~20%, p < 0.01). Carvacrol also induced increased tolerance of C. auris to osmotic stress, suggesting activation of adaptive pathways. Conclusions: Carvacrol exhibits species-specific effects, acting as an antivirulence modulator in M. guilliermondii and C. dubliniensis and attenuating virulence in vivo in C. auris. These findings support the potential of carvacrol as an adjuvant antifungal strategy, particularly against C. auris, and highlight the relevance of targeting virulence traits to reduce selective pressure and limit antifungal resistance.